All In MedTech

Device Trial Radar · NCT04116034

Alfapump Direct Sodium Removal (DSR) Feasibility Study

Alfapump DSR System in the Treatment of Diuretic Resistant Heart Failure Subjects

Last checked: Nov 19, 2026Latest source record: May 28, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

8

Actual

Start

Dec 26, 2019

Primary completion

Apr 15, 2021

Study completion Apr 15, 2021

Sponsor

Lead sponsor
Sequana Medical N.V.Not on our public-company list
Sponsor type
Industry
Collaborators
Yale University
First posted
Oct 4, 2019

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Device feasibility
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

First in Human feasibility and sfafety study of the alfapump DSR system in the treatment of Heart failure subects resistant to diuretic therapy. Up to 10 subjects will be enrolled in up to 3 centres in Belgium and Georgia and will be iplanted with the alfapump DSR system. Subjects will undergo DSR titration during a 2 week hospitalisation period, and will continue titrated DSR therapy as outpatients for 4 more weeks.

Conditions

  • Heart Failure
  • Congestive Heart Failure
  • Cardiorenal Syndrome
  • Volume Overload
  • Sodium Excess
  • Sodium Disorder

Interventions

  • alfapump DSR systemDevice

    Infusion of sodium free Dextrose 10% into peritoneal cavity to remove sodium and fluid using principles of peritoneal dialysis, sodium and ultrafiltrate will be evacuated to the bladder by the alfapump

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety in-hospital - Device relatedTime frame: Through Day 14 of treatment period
  2. Safety in-hospital - therapy relatedTime frame: Through Day 14 of treatment period
  3. Safety in-hospital - procedure relatedTime frame: Through Day 14 of treatment period

3 more outcomes with a free account

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • OLV Ziekenhuis

    Aalst, Belgium

  • Tbilisi Heart & Vascular Clinic

    Tbilisi, Georgia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.